Cartesian Therapeutics Inc — Rendiconto Finanziario (NASDAQ:RNAC) | MetaTrader

Apri il grafico completo

Notizie

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Murat Kalayoglu del consiglio di amministrazione di Cartesian Therapeutics si dimetterà dal 31 marzo

BTIG conferma Buy su Cartesian Therapeutics, target a 44$

BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target

Mizuho conferma il rating su Cartesian Therapeutics per i progressi degli studi

Mizuho reiterates Cartesian Therapeutics stock rating on trial progress

Kyverna Stock: The King Of The CAR-T Autoimmune Revolution (NASDAQ:KYTX)

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?

Johnson & Johnson Touts Positive Results For Lupus Treatment - Johnson & Johnson (NYSE:JNJ)

2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares

H.C. Wainwright riduce il target di prezzo delle azioni di Cartesian Therapeutics a $30 da $40

H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40